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ABSTRACT:
Mantle cell lymphoma (MCL) is considered one of the most challenging lymphoma, 
with limited responses to current therapies. Acadesine, a nucleoside analogue has 
shown antitumoral effects in different preclinical cancer models as well as in a recent 
phase I/II clinical trial conducted in patients with chronic lymphocytic leukemia. Here 
we observed that acadesine exerted a selective antitumoral activity in the majority 
of MCL cell lines and primary MCL samples, independently of adverse cytogenetic 
factors. Moreover, acadesine was highly synergistic, both in vitro and in vivo, with 
the anti-CD20 monoclonal antibody rituximab, commonly used in combination therapy 
for MCL. Gene expression profiling analysis in harvested tumors suggested that 
acadesine modulates immune response, actin cytoskeleton organization and metal 
binding, pointing out a substantial impact on metabolic processes by the nucleoside 
analog. Rituximab also induced changes on metal binding and immune responses.The 
combination of both drugs enhanced the gene signature corresponding to each single 
agent, showing an enrichment of genes involved in inflammation, metabolic stress, 
apoptosis and proliferation. These effects could be important as aberrant apoptotic 
and proinflammatory pathways play a significant role in the pathogenesis of MCL. 
In summary, our results suggest that acadesine exerts a cytotoxic effect in MCL in 
combination with rituximab, by decreasing the proliferative and survival signatures of 
the disease, thus supporting the clinical examination of this strategy in MCL patients.
 INTRODUCTION
Mantle cell lymphoma (MCL) represents 5-10% 
of all non-Hodgkin lymphomas (NHLs) and is one of 
the most aggressive lymphoid neoplasms with poor 
prognosis. Its genetic hallmark is the chromosomal 
translocation t(11;14)(q13;q32), which leads to cyclin D1 
overexpression with the consequent cell cycle deregulation 
[1]. MCL cells carry a high number of secondary genetic 
alterations that increase the oncogenic potential of cyclin 
D1 and frequently inactivate the cellular response to 
DNA damage. In addition, other mechanisms such as 
activation of cell survival pathways are integrated to 
drive MCL pathogenesis. Current frontline combination 
chemotherapies and intensive chemoimmunotherapy 
followed by stem-cell transplantation have improved the 
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outcome for patients with this disease [2]. Although these 
regimens have high initial response rates, most patients 
relapse and die from disease-related complications [1]. The 
introduction of rituximab, a chimeric mouse anti-human 
CD20 monoclonal antibody, has shown improvement of 
response rates when used in combination with standard 
chemotherapy [3;4]. In the last years, new strategies that 
target crucial biological pathways such as ubiquitin-
proteasome system, mTOR pathway and BCR signaling 
have been developed [2;5;6]. In particular, recently it 
has been described that Ibrutinib, a BTK inhibitor shows 
durable single-agent efficacy in relapsed or refractory MCL 
[7]. Acadesine (5-aminoimidazole-4-carboxamide-1-D-
ribofuranoside, AICA-riboside or AICAR) is a nucleoside 
analogue initially developed as a cardioprotective agent, 
with a different mechanism of action compared to standard 
nucleoside analogues, like fludarabine [8]. When added 
to cell cultures or administered to animals or humans, 
acadesine is phosphorylated to AICA-ribotide (ZMP), the 
natural endogenous intermediate in the de novo purine 
nucleotide biosynthesis, which can function as an AMP 
mimic and activate AMP-activated kinase (AMPK), a 
protein that regulates the responses of the cell to energy 
changes [9]. Although acadesine is commonly used as 
an AMPK activator, there are compelling evidences that 
acadesine anti tumoral effects could be mediated, at least 
in part, independently of the AMPK pathway [10-13]. 
Nevertheless, at present, the exact nature of the AMPK-
independent effects of acadesine in leukemic cells is 
not clearly understood. Many studies have shown that 
acadesine can inhibit proliferation, and induce apoptosis in 
multiple myeloma [14], neuroblastoma [15], glioblastoma 
[16], childhood acute lymphoblastic leukemia (ALL) [17], 
colon cancer [18], and breast and prostate cancer cell 
lines [19]. In particular, acadesine exerts a pro-apoptotic 
activity in a wide range of B lymphoid malignancies [20], 
being cells from chronic lymphocytic leukemia (CLL) the 
most sensitive to this agent [13;21]. Recently, a phase I/II 
clinical trial conducted in relapsed/refractory CLL patients 
has demonstrated a remarkable activity of the drug in the 
clinical settings [22]. 
In this study, we show that acadesine exerts a 
specific antitumoral activity in the majority of MCL 
cell lines and primary samples, and synergizes with 
rituximab both in vitro and in vivo. Furthermore, we 
provide gene expression profiling (GEP) data on the 
putative mechanisms of action of acadesine-rituximab 
combination, supporting clinical examination of this 
strategy in MCL patients. 
RESULTS
Acadesine exerts a cytotoxic effect both in MCL 
cell lines and MCL primary samples
Nine MCL cell lines were exposed for 24 or 48 
hours to increasing doses of acadesine ranging from 0.1 
to 2 mM, and IC50 and LD50 values were calculated from 
data obtained by the MTT and the Annexin V assays, 
respectively. As shown on Table 1, most of the cell lines 
analyzed (REC-1, JEKO-1, UPN-1, JVM-2, MAVER-1 
and Z-138) showed a IC50 lower than 1 mM after 48 
hours of acadesine incubation. Three cell lines (MINO, 
HBL-2 and GRANTA-519), showed a IC50 higher than 2 
mM, the maximum dose tested. The analysis of the LD50 
values followed the same pattern, being REC-1, JEKO-
1 and UPN-1 the most sensitive cell lines to acadesine-
induced cell death, with LD50 below 1 mM after 48 hours 
of incubation (Figure 1A and 1C). Z-138, JVM-2 and 
MAVER-1 cell lines showed LD50 around 1.5 mM at 48 
hours and, accordingly to the MTT assay results, MINO, 
HBL-2 and GRANTA-519 exhibited low sensitivity to 
acadesine with a not-reachable LD50. Acadesine-evoked 
cell death increased in a time- and a dose-dependent 
manner, as illustrated in Figure 1A. Deletion at 17p, 
affecting TP53 or the total amount of copy number 
alterations (CNA), including trisomies or monosomies that 
carried most of the MCL cell lines (Table 1) did not affect 
the susceptibility of MCL cells to acadesine.
Then, isolated tumor cells from 15 MCL samples 
were exposed for 24 hours to acadesine 1 and 2 mM, and 
cell viability was analyzed by annexin V labeling. As 
shown on Table 1 and illustrated on figure 1C, similarly to 
what observed in MCL cell lines, acadesine also induced 
apoptosis in primary patient cells, even though this effect 
was heterogeneous among our set of MCL primary 
cultures (Figure 1B). Six out of fifteen cases (40%) 
showed a response above 25 % to 1 mM acadesine, while 
12 of 15 cases (80%) achieved these responses at 2 mM 
acadesine, being the mean cytotoxicity at this dose 48.28 ± 
27.97%. Again, no association could be observed between 
the response to acadesine and the presence of TP53 
anomalies and CNAs in the set of primary MCL samples 
studied. Despite all of them harbored a high percentage of 
tumoral B-cells (range 76-97%) (Table 1), we analyzed the 
activity of acadesine in B-tumoral and the accompanying 
T-cells in 10 out of the 15 MCL cases studied. Using a 
triple CD19/CD3/Annexin V labeling, we found that B 
tumor cells (CD19+) were significantly more sensitive to 
a 2 mM dose of the drug than the normal T-cell subset, 
both at 24 and 48 hours (Figure 1D, P<0.01 at 24 hours 
and P<0.001 at 48 hours).
Altogether, these results suggest that acadesine 
is active in the majority of MCL cell lines and primary 
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samples, where it exerts a selective antitumoral effect, 
regardless of genetic alterations and adverse prognostic 
factors.
Acadesine and rituximab exert a synergistic 
cytotoxic effect 
We further investigated potential interactions of 
acadesine with drugs currently approved for the treatment 
of relapsed/refractory MCL, including bortezomib, 
bendamustine and rituximab. For this aim, a panel of MCL 
cell lines were incubated for 48 hours with two different 
doses of acadesine (0.5 and 1 mM), bortezomib (2.5 and 
5 nM) and bendamustine (25 and 50 µM). Rituximab 
experiments were performed after incubation of cells 
for 24 h with acadesine, followed by an additional 24 h 
incubation with or without two different concentrations of 
rituximab (20 and 40 µg/mL), except for JEKO-1 cells 
where rituximab was used at 1 and 2 µg/ml. Inhibition 
of proliferation was measured using the MTT assay. Then 
the combination index (CI) using the Chou and Talalay 
method were evaluated for each drug combination and 
represented in Figure 2A. An antagonistic effect was 
observed when acadesine was combined with 5 nM 
bortezomib. When used in combination with bendamustine 
25 µM , acadesine displayed either additive or synergistic 
cytotoxic activity, depending on the MCL cell line, and 
being the cell lines carrying a P53 wild type phenotype 
those with the higher synergistic effect between these two 
drugs. Interestingly, a synergistic effect of acadesine plus 
rituximab was observed in 7 out of the 9 MCL cell lines 
Figure 1: Acadesine induces cytotoxicity in both MCL cell lines and MCL primary samples. A. MCL cell lines were 
incubated with acadesine 1 mM and 2 mM for 24 and 48 hours and cytotoxicity was measured by Annexin V labeling. Data show the 
mean ± SEM of three independent experiments. B. Primary MCL cells were incubated with acadesine 1 mM and 2 mM for 24 hours and 
cytotoxicity was measured as above. Data show the mean ± SEM of three replicates. C. Representative flow cytometric plots of Annexin V/
Propidium iodide labeling in a representative MCL cell line (JEKO-1) and a primary MCL sample (MCL#12) treated with acadesine 2 mM 
for 24 hours. D. Acadesine cytotoxicity in B tumoral and T normal lymphocytes from MCL cases. Results show the mean cytotoxicity of 
10 primary MCL samples ± SEM analyzed after incubation with acadesine 2 mM for 24 hours. (** P< 0.01, *** P< 0.001)
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tested, with CI values ranging from 0.400 to 0.918, with 
no correlation with any known MCL genetic alteration 
(Table 1). The two remaining MCL cell lines (MAVER-1 
and GRANTA-519), showed CI values closed to 1, 
indicative of an additive or a slightly antagonistic effect.  
In 5 MCL primary samples, the combination of 
acadesine with rituximab was also synergistic at all 
the concentrations tested (Table 1), being the best drug 
interaction obtained with acadesine 1 mM and rituximab 
40 µg/ml (mean CI = 0.597 ± 0.102, Figure 2C). 
Importantly, the synergistic effect observed in primary 
MCL cells was independent of the initial response to 
acadesine, being rituximab able to sensitize MCL cells 
and to overcome their resistance to the nucleoside analog.
To validate the specificity of the cooperation 
between acadesine and rituximab in MCL, we evaluated 
the cytotoxic effect of both drugs either alone or in 
combination in two CLL cell lines, namely MEC-1 and 
MEC-2, and in a set of 4 primary CLL cultures. We 
observed that in CLL cells the acadesine-combination 
lacked the synergistic activity observed in MCL cells, with 
CI values ranging from 1.181 to 8.336, being additive in 
the MEC-1 cell line and antagonistic in the MEC-2 cell 
line, as well as in all the CLL primary samples tested (data 
not shown). 
Altogether, these results suggest that among the 
standard agents currently used in the clinical, rituximab 
presents the best combinational activity with acadesine, 
and that this effect may be specific for the MCL model.
The combination of acadesine and rituximab 
inhibits tumor outgrowth in a mouse xenograft 
model of MCL
To validate the synergism between acadesine 
and rituximab observed in JEKO-1, we evaluated the 
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antitumoral effect of this combination in a CB17-
SCID mouse xenograft model of MCL generated using 
this cell line. Animals were randomly assigned into 
different groups with 6 mice per cohort and treated with 
acadesine at dose level of 400 mg/kg body weight five 
days a week, rituximab at 10 mg/kg body weight once a 
week, both drugs as above or the equivalent volume of 
vehicle. When compared to vehicle-treated mice, after 
18 days of treatment, we observed that tumor burden 
was significantly reduced in mice treated either with 
acadesine (P<0.01) or with rituximab (P<0.001) as single 
agents. We observed a reduction in tumor size of 31.22 
± 15.68% in acadesine-receiving animals and of 63.85 ± 
10.88% in the rituximab arm. The combination of both 
agents was significantly more effective than the two drugs 
alone (P<0.001 compared to acadesine, P<0.01 respect 
to rituximab) leading to an almost complete inhibition 
of tumor growth (Figure 3A). Mice tolerated well the 
treatment, and no effect on animal vital parameters was 
reported, in any of the treatment arms. Thus, these results 
suggest that the combination of acadesine with rituximab 
might represent a safe and efficient therapeutic approach 
for the treatment of MCL tumors.
Figure 2: Acadesine shows a synergistic effect with 
rituximab in vitro and in vivo. A. Acadesine was combined 
with bortezomib, bendamustine and rituximab in a panel of 9 
MCL lines and inhibition of proliferation was analyzed by the 
MTT assay. The graph shows the CI of the combination of 
acadesine 1 mM with bortezomib 5 nM, bendamustine 25 µM, 
and rituximab 40 µg/ml (1 µg/ml for JEKO-1) for each cell line. 
The combinations with CI > 2 are not shown in the graph. B. 
Combination of acadesine with rituximab in JEKO-1 cell line. 
Cells were pre-incubated for 24 hours with acadesine, followed 
by a 24-hour exposure to rituximab. Inhibition of proliferation 
was analyzed by the MTT assay. Data show the results of three 
independent experiments ± SEM and CI are indicated above 
the bars. C. Combination of acadesine with rituximab in MCL 
primary samples. Primary cells were incubated with acadesine 
and rituximab as above. Data show the mean of 5 samples ± 
SEM and CI are indicated above the bars.
Figure 3: Acadesine-rituximab combination inhibits 
MCL tumor outgrowth. A. SCID mice were inoculated 
subcutaneously with JEKO-1 cells and treated with acadesine 
(400 mg/kg 5 days a week), rituximab (10 mg/kg once a week) 
or both drugs. Tumor growth is represented as the mean ± SEM 
(n=6) (** P< 0.01, *** P< 0.001)
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Figure 4: Gene expression profile analysis of mice-treated tumors. GEP analysis of tumors was performed and graph shows the 
number of differentially expressed genes from each treatment compared to the control with a FDR below 0.2 and an absolute FC above 
1.4 B. Heatmap displaying genes modulated by the combination clustered according to GO terms. Relative gene expression levels are 
color-coded as indicated at the bottom. C: control; A: acadesine; R: rituximab; AR: combination. C. Immunostaining of harvested tumors 
of mouse xenograft MCL after acadesine, rituximab and acadesine-rituximab treatment. Histological sections from representative tumors 
of each treatment stained with hematoxylin and eosin and specific antibodies against metallothionein, activated caspase-3 and phospho-
histone 3 (x40) D. JEKO-1 cells were treated with acadesine, rituximab and the combination after a CD40L + IL-4 stimulation and 
inhibition of proliferation was measured by MTT assay. Data show the mean of three independent experiments ± SEM. E. Migration assay 
of JEKO-1 cells treated with acadesine, rituximab and the combination. Graph shows the number of CXCL12-stimulated cells migrating 
after each treatment.
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The combination of acadesine and rituximab 
modulates genes related to inflammation, 
metabolic stress, proliferation and survival 
pathways in MCL 
In order to understand the basis of the synergy 
between acadesine and rituximab, we next examined 
changes in gene expression profiles in a set of 
representative harvested tumors from each cohort (n=3 
tumors/group). We determined the differentially expressed 
genes from each treatment compared to the control with 
a false discovery rate (FDR) below 0.2 and an absolute 
fold change (FC) above 1.4 using the Rank Products 
method in the TM4-MEV platform. Treating the cells 
with acadesine was associated with the lowest number of 
gene modulations (18 genes up-regulated and 41 genes 
down-regulated), whereas after rituximab treatment 
26 genes were up-regulated and 46 genes were down-
regulated. Acadesine and rituximab treatment affected the 
expression of a much higher number of genes, being 481 
genes up-regulated and 512 genes down-regulated (Figure 
4A and Supplemental Table 1). To gain insight into the 
biological function of the treatment-related differential 
expression profiles, we conducted a gene onthology (GO) 
enrichment analysis using the DAVID application. Both 
acadesine and rituximab monotherapies were found to 
be related to an enrichment of genes involved in metal 
binding and immune response, while genes related to actin 
cytoskeleton organization and immune response, were 
more specifically regulated by acadesine and rituximab, 
respectively. Importantly, the treatment with acadesine-
rituximab combination allowed to the identification of 
the same GO terms, but with improved significance 
(P<0.001). Additionally, an enrichment of genes related to 
regulation of cell death and cell proliferation was detected 
in tumors receiving this combination (Table 2). Figure 
4B showed an overview of the genes modulated by the 
combination clustered according to the previous described 
GO terms. 
Then, GSEA was used to identify the gene-sets 
and pathways modulated by each treatment considering 
a FDR<0.05 (Table 3). For acadesine, the statistically 
significant normalized enrichment scores (NES) were 
achieved by the metallothionein node (NES=-1.92) 
and the WNT pathway (NES=-1.97). In tumors treated 
with rituximab, we found also an enrichment of the 
metallothionein node (NES=-1.86). Furthermore, 
pathways involved in B/T cell calcium signaling (NES=-
1.87), CD40 (NES=-1.89) and NF-κB pathways (NES=-
1.91) were also down-regulated. A significant regulation 
of all these pathways, except for WNT, was also observed 
in tumors treated with the drug combination. Additionally, 
we observed down-regulation of genes involved in 
inflammatory response (NES=-2.02), apoptosis (NES=-
1.88), metabolic stress (NES=-1.87), as well as interferon 
signaling (NES=-2.82) and Toll pathway (NES=-1.83), 
both of them involved in inflammation (Table 3). 
In an attempt to validate the relevance of some of 
these profiles at the functional level, we first selected 
to analyze the variation of the metallothionein node, 
by immunohistochemical detection of metallothionein 
proteins in the different treatment groups. For this aim, 
histologic sections from representative whole tumors were 
labeled with specific antibodies against metallothionein as 
indicated in material and methods. As shown on figure 
4D (panel MT), and in accordance with our GEP results, 
down-regulation of MT staining was observed in both 
acadesine- and rituximab-treated groups, that became 
almost complete in the combination-treated tumors.
Regarding the immune response profile, as the 
GSEA analysis identified the cytokine receptor CD40 
among the main components of this profile, and as it 
has been reported that CD40 participates in the survival, 
cell growth, and drug resistance in MCL [23], we 
performed a co-stimulation assay of JEKO-1 cells with 
recombinant CD40L + interleukin-4 (IL4), followed by 
cell exposure to the different drugs and determination 
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of cell viability. As shown on figure 4D, stimulation of 
MCL cells with CD40L+IL4 did not prevent the decrease 
in cell proliferation either in acadesine, rituximab-, or 
the combination, contrasting with what observed when 
MCL cells were incubated with bortezomib. These results 
suggest that CD40 pro-survival signaling does not affect 
significantly the acadesine-rituximab cytotoxic activity in 
MCL cells.
Next, as the actin cytoskeleton organization node 
contained genes related to the migration of cells, we 
performed chemotaxis assays in JEKO-1 cells exposed to 
acadesine, rituximab and the combination. We observed 
that both agents were able to inhibit the migration of 
JEKO-1 cells, and that this effect was higher in cells 
treated with the combination (Figure 4E).
Finally, and in agreement with our DAVID analysis, 
showing that the regulation of cell death and proliferation 
were significantly affected by acadesine-rituximab 
combination in MCL tumors, by immunohistochemistry 
we observed a higher expression of the activated form of 
caspase-3 (figure 4C, panel act.Casp3) and a reduction 
in the phosphorylation status of the proliferation marker 
histone H3 (figure 4C, panel Phospho-H3), in the tumor 
tissues treated with acadesine plus rituximab, when 
compared to vehicle- and single agent-treated tumors.   
In summary, the combination of both acadesine and 
rituximab enhanced the gene signature corresponding 
to each single agent, showing an enrichment of genes 
involved in inflammation, metabolic stress, apoptosis 
and proliferation. These effects could be important as 
aberrant apoptotic and proinflammatory pathways play an 
important role in the pathogenesis of MCL.
DISCUSSION
Acadesine has demonstrated to efficiently block 
cell proliferation in several tumor models, in association 
with decreased fatty acid and protein synthesis [24]. 
Besides inhibiting cell proliferation, acadesine induces 
also apoptosis in different tumor cell types [13;15;21;25-
27] and autophagy [28]. Recently, the first phase I/II trial 
has been conducted in relapsed/refractory CLL patients 
showing a manageable and safe profile and with the 
conclusion that acadesine may represent a valuable agent 
for the treatment of this entity [22].
In the present study we show that acadesine exerts a 
pro-apoptotic effect in the majority of MCL primary cells 
and cell lines in a time- and dose-dependent manner, at 
physiologically achievable doses. The LD50 values are 
slightly higher than those observed in CLL cells, which 
showed a LD50 of 380 ± 60 μM [21], but similar to those 
reported previously in a reduced subset of MCL cases 
[20]. Interestingly, the maximum acadesine dose tested 
in our experiments (2 mM), did not induce apoptosis 
in accompanying T-cells from any of the MCL cases 
analyzed, thus arguing in favor of the specificity of the 
drug. The same specificity for tumoral B cells have been 
described in the CLL model [21], that sharply contrasts 
with the lack of selectivity of other anti-leukemic 
drugs, like conventional nucleoside analogs [29]. Our 
results demonstrate that MCL response to acadesine is 
independent of TP53 status and that it is not affected by 
the occurrence of CNAs. The situation seems to differ 
from other cell types, as it has been recently described 
that acadesine elicited a selective apoptotic response 
in trisomic mouse embryonic fibroblasts [30] and 
chromosomal instability-driven colorectal cancer cell lines 
[31].
The clinical course of MCL is characterized by an 
initial high response rate but a constant relapse pattern, 
resulting in a poor long-term outcome [2]. It has been 
reported that first-line chemotherapy including rituximab 
is associated with significantly improved survival in 
older patients diagnosed with MCL compared with 
chemotherapy alone [3]. In the last years, the proteasome 
inhibitor bortezomib and bendamustine, an hybrid 
drug between a nucleoside analog and an alkylating 
agent, have been approved in USA for the treatment of 
patients with relapsed MCL patients, either alone or in 
combination with rituximab [2]. Here, we observed an 
antagonistic effect between bortezomib and acadesine 
whereas for bendamustine we detected an additive 
or synergistic effect depending on the MCL cell line. 
Our results demonstrated that rituximab is the best 
useful complementary drug to use in combination with 
acadesine, compared with bendamustine and bortezomib. 
The efficacy of the acadesine-rituximab combination 
was independent of TP53 mutational status in MCL 
cells, whereas the synergism effect of acadesine plus 
bendamustine was higher in cell lines with P53 wild type 
phenotype, consistently with the known role of P53 in 
MCL cell response to bendamustine [32]. Importantly, 
this synergistic effect between acadesine and rituximab 
appeared to be specific for MCL, as it was not observed 
in CLL cells. The synergistic in vitro effect between 
acadesine and rituximab was then confirmed in vivo 
using a xenograft mouse model, where a remarkable 
regression of the tumor was observed in animals dosed 
with the drug combination. The antineoplastic effect of 
acadesine alone has already been reported on the growth 
of mice xenograft models of prostatic tumors [19], CML 
[28] and retinoblastoma [33]. Our in vivo results using a 
xenograft model showed that the treatment with acadesine 
had a modest anti tumoral activity, suggesting that this 
drug alone could have limited therapeutic application as a 
single agent. In contrast, an important anti tumoral activity 
was observed when combined with rituximab, leading 
to almost complete inhibition of tumor growth. These 
results are in agreement with the notion that rituximab 
significantly improves the response rates in MCL patients 
when used in combination with standard chemotherapy 
[2-4], as well as with the last agents approved for the 
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treatment of relapsed/refractory MCL patients, like 
bortezomib [34], temsirolimus [35], and lenalidomide 
[36]. Based on our present results, acadesine-rituximab 
may also warrant potential use in the clinical practice.
To date, there is still no absolute consensus of the 
in vivo mechanism of action of rituximab or rituximab-
based combination. Based on in vitro studies, rituximab 
appears to mediate the depletion of B-cells by several 
mechanisms that are dependent on the host immune 
system, including complement-dependent and antibody-
dependent cellular cytotoxicities [37-39]. It has also been 
proposed that rituximab might sensitize lymphoma cells 
to chemotherapy, and have direct antiproliferative and 
apoptotic effects [38]. Using a GEP approach, we aimed 
to know the signaling pathways by which acadesine exerts 
its anti-tumor effect in combination with rituximab. We 
observed that the number of genes down- and up-regulated 
after acadesine and rituximab treatments as single agents 
was low, but that it increased notably with the combination 
treatment in line with the observed tumor burden 
inhibition. We found 5 GO terms differentially expressed: 
metal binding, immune response, actin cytoskeleton 
organization and regulation of cell death and proliferation. 
Acadesine alone was able to modulate immune response, 
actin cytoskeleton organization and metal binding, 
having a substantial impact of the drug toward metabolic 
processes, accordingly to a recent microRNA analysis 
in acadesine-exposed hepatocytes [40]. Rituximab also 
induced changes on metal binding and immune responses. 
Accordingly, it has been reported that rituximab was 
capable of inducing a calcium flux in B-cells through its 
ability to associate with B-cell receptor (BCR) [41]. CD20 
activity is also known to be associated with BCR activation 
through the induction of Src family tyrosine kinases and 
the activation of the MAPK pathway [42]. Conversely, 
rituximab has been shown to inhibit BCR signaling, and 
different signaling pathways involving MAPK, PI3K/
Akt, NF-κB and mTOR kinases [43]. Among the metal 
binding core of genes, we observed a decrease in genes 
implicated in response to metal ion and negative regulation 
of cell growth, namely MT1G and MT1X, that codify 
for two members of the metallothionein family, whose 
expression has been reported to constitute an independent 
risk factor in diffuse large B cell lymphoma [44]. We 
confirmed by inmunohistochemistry the downregulation 
of these metallothionein proteins in tumors from the three 
treatment arms, but especially in tumors having received 
the combination of drugs. Similarly, when considering 
the immune response profile in the combo group by GEP 
analysis, we observed an accentuated downregulation of 
the CD40 signaling pathway. It has been described that 
the microenvironment, including cytokines, has a central 
role on MCL cell survival and drug resistance, and that the 
CD40 system acts as a growth-promoting stimulus [23]. 
Thus, pharmacological interference with this signaling 
pathway may have therapeutical relevance in MCL, as 
demonstrated by the use of the CD40-targeting antibody 
dacetuzumab in combination with rituximab in in vitro 
and in vivo models of MCL [45]. Of special relevance, we 
observed that acadesine, rituximab and their combination 
were able to overcome the CD40 pro-survival effect in 
MCL cells, offering a glimpse for further combination 
therapy in this model. Finally, our results also showed 
that acadesine and acadesine-based combination interfere 
with migration in MCL cells. Accordingly, it has been 
reported that acadesine significantly inhibits the growth of 
tumors in nude mice xenotransplants of retinoblastoma, 
by inducing apoptosis and suppressing tumor angiogenesis 
and macrophage infiltration [33]. Of importance, acadesine 
and rituximab combination therapy resulted in enhanced 
cell death in MCL cell lines and primary tumor samples 
and increased regression of tumor burden in an in vivo 
murine model of MCL. 
In summary, our GEP analysis, together with our 
histological and functional validation studies, suggest that 
by mainly decreasing the proliferative and survival gene 
signatures that drive MCL cell growth, the combination 
strategy associating rituximab to acadesine may represent 
a new effective therapy to improve MCL patients’ outcome 
and to reduce treatment-associated toxicities.
METHODS
Cell lines
Nine human MCL cell lines (GRANTA-519, JVM-
2, JEKO-1, Z-138, MAVER-1, REC-1, UPN-1, HBL-2 
and MINO) and two CLL cell lines (MEC-1 and MEC-2) 
were cultured with RPMI 1640, DMEM or IMDM media 
complemented with 10-20% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, 50 μg/ml penicillin/
streptomycin (Life Technologies). Cells were grown in a 
humidified atmosphere at 37Cº with 5% carbon dioxide 
and routinely tested for Mycoplasma absence by PCR. 
Additionally, the genetic identity of all cell lines was 
verified periodically using the AmpFISTR identifier kit 
(Life Technologies). Genetic characterization of the MCL 
cell lines is shown in Table 1.
Primary cultures
Primary cells were obtained from peripheral 
blood samples of leukemic MCL and CLL patients 
diagnosed according the WHO criteria. The study was 
done in accordance with protocols approved by the 
Ethic Committee of the Hospital Clinic of Barcelona. 
All patients signed an informed consent according to 
the Declaration of Helsinki. Biological characteristics 
of MCL cases are shown in Table 1. Mononuclear cells 
were isolated by centrifugation on a Ficoll-Hypaque 
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(GE Healthcare) gradient and conserved within the 
Hematopathology collection of our institution. Cells were 
either used directly or cryopreserved in liquid nitrogen in 
the presence of 10% dimethyl sulfoxide, 60% FBS and 
30% RPMI 1640. Cells were cultured in a supplemented 
RPMI medium likewise cell lines.
Assays of cytotoxicity 
MCL cell lines were incubated with acadesine 
(kindly provided by Advancell) at doses ranging from 0.1 
to 2 mM for 24 or 48 hours. Inhibition of proliferation 
was measured using the MTT assay and the IC50 was 
defined as the concentration of drug required to reduce 
cell proliferation by 50%. Cell viability was quantified 
after dual staining of cells with annexin V-fluorescein 
isothiocyanate (FITC)-conjugated and propidium iodide 
(PI) (Bender Medsystems), followed by flow cytometry 
analysis on a FACScan flow cytometer using CellQuest 
and Paint-A-Gate softwares (Becton Dickinson). Lethal 
dose 50 (LD50) was defined as the concentration of drug 
required to reduce cell viability by 50%. 
Primary MCL cells were incubated with acadesine 
at two different doses (1 and 2 mM) for 24 hours. In 
these samples, the viability of tumoral B (CD19+) and 
accompanying T (CD3+) cells was simultaneously 
analyzed by triple labeling of the samples with anti-CD19-
phycoerythrin (PE) and anti-CD3-FITC antibodies (Becton 
Dickinson), and allophycocyanin (APC)-conjugated 
annexin V (Bender Medsytems) on a FACScalibur flow 
cytometer.
For bendamustine and bortezomib combinations, 
MCL lines were incubated simultaneously with acadesine 
(0.5 and 1 mM), and bortezomib (2.5 and 5 nM) or 
bendamustine (25 and 50 μM) for 48 hours. Cytotoxicity 
was analyzed by the MTT assay. Combination indexes (CI) 
were analyzed with Calcusyn software (Biosoft), based in 
the Chou & Talalay’s method [46]. Drug combinations 
with a CI lower than 1.0 were considered as synergistic.
For acadesine-rituximab studies, cell lines were 
pre-incubated for 24 hours with acadesine (0.5 and 1 
mM for MCL cells and CLL cell lines, 0.1 and 0.25 for 
CLL primary cases), followed by a 24 hour exposure to 
20 and 40 µg/ml of rituximab (1 and 2 µg/ml for JEKO-
1 cells). Because rituximab induces cytotoxicity in part 
by a complement-mediated mechanism [39], we added 
10% of human AB plasma together with rituximab as a 
source of complement proteins. Cytotoxicity and CI values 
were quantified as above. When indicated, cells were 
exposed to 1 μg/ml of recombinant human soluble CD40L 
(rhsCD40L, Sigma) and 20 ng/ml IL-4 (R&D Systems) 1 
h before acadesine exposure. 
Xenograft mouse model
Female 6 to 8-week-old CB17-severe combined 
inmunodeficiency (SCID) mice (Charles River 
Laboratories Inc) were bred under pathogen-free 
conditions at the animal facility of our institution using 
a protocol approved by the Animal Testing Ethical 
Committee of the University of Barcelona (CEAA). 
Mice were inoculated subcutaneously in the right 
flank with 1x107 JEKO-1 cells in MatrigelTM Basement 
Membrane Matrix (1:1) (Becton Dickinson). When tumors 
were palpable and reached a volume of approximately 
200 mm3, animals were randomly assigned into different 
groups with 6 mice per cohort and treated with acadesine 
at dose level of 400 mg/kg body weight five days a week, 
rituximab at 10 mg/kg body weight once a week, both 
drugs as above or the equivalent volume of vehicle, for 
18 days. The shortest and longest diameters of the tumor 
were measured with external calipers twice a week. Tumor 
volume was calculated using the following standard 
formula: (the shortest diameter)2 x (the longest diameter) 
x 0.5. Mice were sacrificed at the end of the treatment 
according to institutional guidelines. Harvested tumors 
were snap-frozen in Tissue-Tek® O.C.T. medium (Sakura 
Tissue Tek) or formalin-fixed before paraffin embedding 
on silane-coated slides in a fully automated immunostainer 
(Bond Max; Vision Biosystems). 
Gene expression studies
Total RNA was extracted from 3 representative 
harvested tumors of each group, using the RNeasy Mini 
Kit (Qiagen). RNA quality and quantity was determined 
using a 2100 Bioanalyzer (Agilent Technologies) and 
only high quality RNA samples were processed to 
Affymetrix GeneChip HT HG-U219 arrays. Sample 
preparation for microarray hybridization was performed 
following Affymetrix’s protocols. Briefly, from 150 ng 
of total RNA, a biotin labeled cRNA was generated by 
reverse transcription. Following cRNA fragmentation, the 
sample was hybridized on the GeneChip HT HG-U219 
perfect-match-only (PM) Array Plate. After hybridization 
and washes, scanning was processed in the Gene Titan 
instrument, a fully automated array system. The analysis 
of the scanned images and the determination of the signal 
value for each probe set of the array were obtained with 
GeneChip® Command Console® Software (AGCC) 
(Affymetrix). Raw data were normalized using the Robust 
Multichip Analysis (RMA) algorithm of the BioConductor 
Affy Package. 
Differential expression data analysis was carried 
out using the Multiexperiment Viewer Platform (TM4-
MEV) [47]. To compare each treatment to the control, we 
determined the number of statistically significant up- and 
down-regulated genes using Rank Products methodology 
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[48] setting up a false discovery rate (FDR) below 0.2 and 
an absolute fold change (FC) above 1.4. 
Gene function was assigned based on Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID) tool (http://www.david.abcc.ncifcrf.gov) and 
Gene Ontology (http://www.geneontology.org) in terms 
of biological process and molecular function. Gene sets 
with a P value below 0.05 were considered as significant. 
Primary microarray data are available at the Gene 
Expression Omnibus (GEO) of the National Center for 
Biotechnology Information (GSE47871). 
An enrichment pathway analysis was done using the 
gene set enrichment analysis (GSEA) desktop application 
version 2.0 (GSEA, Broad Institute at MIT, Cambridge, 
MA; http://www.broadinstitute.org/gsea/) in order to find 
significant gene signatures using experimentally derived 
custom gene sets. Gene sets were downloaded from http://
lymphochip.nih.gov/signaturedb/index.html. A two-
class analysis with 1,000 permutations of gene sets and a 
weighted metric was used. Gene sets with FDR below 0.05 
were considered as significant.
Immunohistochemistry staining 
Immunohistochemical staining studies were 
performed as previously described [49]. The following 
antibodies were used: anti-metallothionein (Dako) that 
recognizes the metallothionein isoforms 1 and 2, anti–
cleaved caspase-3 (Cell Signaling Technology) and anti–
phospho-Histone H3 (Epitomics). Preparations were 
evaluated with an Olympus DP70 microscope by means of 
a 40×/0.75 NA objective and DPManager software v2.1.1 
(Olympus). 
Chemotaxis studies
JEKO-1 cells (107 cells/mL) were washed twice and 
serum-starved for 1.5 hours in FBS-free RPMI. Acadesine 
1 mM and rituximab 2 μg/ml were added simultaneously 
for 3 additional hours, and cells were diluted to 5 × 
106 cells/mL with 0.5% bovine serum albumin (BSA; 
Sigma) in RPMI. One hundred microliters (5 × 105 cells) 
was added to the top chamber of a Transwell culture 
polycarbonate insert with 6.5-mm diameter and 5 μm 
of pore size (Corning). Inserts had been previously 
transferred to wells containing 600 μL of RPMI with 200 
ng/mL of human recombinant CXCL12 (Peprotech). After 
3 hours of incubation at 37°C, 100 μL was collected in 
triplicate from each lower chamber and counted by flow 
cytometry (Attune, Life technologies) for 12 seconds 
under constant flow rate. Migration is represented as the 
number of CXCL12-stimulated migrating cells.
Statistical analysis
All statistical analysis were performed using 
GraphPad Prism 4.0 Software (Graphpad Software). 
Comparison of means between two groups of samples was 
evaluated by non-parametric Mann-Whitney test. Results 
were considered statistically significant when P≤ 0.05 
(*P<0.05, **P<0.01, ***P<0.001).
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